• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avita Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    2/12/26 4:15:26 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care
    Get the next $RCEL alert in real time by email
    8-K
    false000176230300017623032026-02-122026-02-12

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): February 12, 2026

     

     

    AVITA Medical, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-39059

    85-1021707

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    28159 Avenue Stanford

    Suite 220

     

    Valencia, California

     

    91355

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 661 367-9170

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    RCEL

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 2.02 Results of Operations and Financial Condition.

    On February 12, 2026, the Company issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information furnished in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit No.

     

    Description of Exhibit

    99.1

     

    Press release, dated February 12, 2026, issued by AVITA Medical, Inc.

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    AVITA Medical, Inc.

     

     

     

     

    Date:

    February 12, 2026

    By:

    /s/ David O’Toole

     

     

     

    David O’Toole
    Chief Financial Officer

     

     


    Get the next $RCEL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RCEL

    DatePrice TargetRatingAnalyst
    5/15/2026$6.00Hold → Buy
    Lake Street
    3/5/2026$10.00Outperform
    Northland Capital
    11/20/2025Sell → Neutral
    BTIG Research
    8/8/2025$3.00Neutral → Sell
    BTIG Research
    12/24/2024$25.00Buy
    D. Boral Capital
    4/11/2024Buy → Neutral
    BTIG Research
    6/27/2023$23.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $RCEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Woody Joseph Fralin bought $84,936 worth of shares (20,000 units at $4.25) (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    6/3/26 4:30:16 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    CFO O'Toole David D bought $8,520 worth of shares (2,000 units at $4.26), increasing direct ownership by 1% to 145,927 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    5/20/26 4:30:06 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    CFO O'Toole David D bought $8,480 worth of shares (2,000 units at $4.24), increasing direct ownership by 1% to 143,927 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    5/19/26 4:30:02 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AVITA Medical to Host Investor Webinar Briefing

    VALENCIA, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer, on May 20, 2026, at 4:00 p.m. Pacific Time (May 21, 2026, at 9:00 a.m. Australian Eastern Standard Time). The webinar presentation will cover financial and business results from AVITA Medical's recent first quarter 2026 earnings webcast and will conclude with a Q&A session. Participants are invited to submit thei

    5/17/26 6:00:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical Reports First Quarter 2026 Financial Results

    VALENCIA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions ("AVITA Medical," or the "Company"), today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights and Recent Business Updates Total revenue of approximately $19.3 million, up 4% year-over-year and approximately 10% sequentially, driven by contributions from Cohealyx® and improved RECELL® utilization as reimbursement dynamics normalizeAppointment of Cary Vance as President and Chief Executive Officer following a comprehensive search process led by a specia

    5/14/26 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical Names Cary Vance as Chief Executive Officer

    Board appoints Cary Vance as President and Chief Executive Officer Follows successful interim tenure and thorough search process by the Board Jan Stern Reed elected as Chair of the AVITA Medical Board VALENCIA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that its Board of Directors has appointed Cary Vance as President and Chief Executive Officer, effective immediately. The Board of Directors has also appointed Jan Stern Reed as its Chair, effective immediately. Mr. Vance, who has served as Interim CEO since October 2025, will continue to serve on the Board as an executive member.

    4/30/26 8:50:00 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    SEC Filings

    View All

    SEC Form 10-Q filed by Avita Medical Inc.

    10-Q - AVITA Medical, Inc. (0001762303) (Filer)

    5/14/26 4:20:41 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Avita Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AVITA Medical, Inc. (0001762303) (Filer)

    5/14/26 4:10:17 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Avita Medical Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AVITA Medical, Inc. (0001762303) (Filer)

    5/1/26 4:54:15 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mcnamara Robert was granted 22,214 shares, increasing direct ownership by 26% to 108,985 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    6/4/26 7:39:08 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Director Woody Joseph Fralin was granted 62,761 shares, increasing direct ownership by 314% to 82,761 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    6/4/26 7:10:02 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Director Tarnoff Michael E was granted 48,464 shares (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    6/4/26 7:09:40 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Avita Medical upgraded by Lake Street with a new price target

    Lake Street upgraded Avita Medical from Hold to Buy and set a new price target of $6.00

    5/15/26 7:56:04 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Northland Capital initiated coverage on Avita Medical with a new price target

    Northland Capital initiated coverage of Avita Medical with a rating of Outperform and set a new price target of $10.00

    3/5/26 8:30:26 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Avita Medical upgraded by BTIG Research

    BTIG Research upgraded Avita Medical from Sell to Neutral

    11/20/25 7:57:06 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Leadership Updates

    Live Leadership Updates

    View All

    AVITA Medical Announces Changes to its Board of Directors

    Veteran healthcare executive Joe Woody joins the BoardLou Panaccio retires after over a decade of service VALENCIA, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the appointment of Joe Woody as a new non-executive Director and the retirement of Lou Panaccio, who served as Chairman from July 2014 to August 2025. "We are pleased to welcome Joe to the Board. His extensive track record leading global med-tech companies and driving commercial excellence will be invaluable as we continue to scale AVITA Medical's growth," said Cary Vance, Interim CEO of

    1/5/26 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical Announces CEO Transition

    Board Chairman Cary Vance appointed Interim CEOBoard member Jan Stern Reed appointed Lead Independent DirectorThird quarter 2025 preliminary revenue expected to be approximately $17 million VALENCIA, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)) ("AVITA Medical", or the "Company"), a leading therapeutic acute wound care company, today announced that the Board of Directors has named Chairman of the Board Cary Vance as Interim Chief Executive Officer, effective immediately. In conjunction with this appointment, Jim Corbett is leaving his positions as CEO and member of the Board. Mr. Vance will continue to serve as Chairman of the Board, while Board m

    10/16/25 6:15:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical Announces Appointment of Michael Tarnoff, MD, FACS, to its Board of Directors and Transition of Board Chair Role to Cary Vance

    Dr. Tarnoff brings extensive executive and medical leadership experience from various organizations, including Tufts Medical Center and Medtronic.The Board thanks Lou Panaccio, its long-standing Board Chair, for his service as he steps down and Cary Vance assumes the Chair position. VALENCIA, Calif. and MELBOURNE, Australia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, announced today the appointment to its Board of Directors (the "Board") of Michael Tarnoff, MD, FACS, as a non-executive Director, effective August 6, 2025. Dr. Tarnoff's appointment comes as the Company fu

    8/6/25 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Financials

    Live finance-specific insights

    View All

    AVITA Medical Reports First Quarter 2026 Financial Results

    VALENCIA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions ("AVITA Medical," or the "Company"), today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights and Recent Business Updates Total revenue of approximately $19.3 million, up 4% year-over-year and approximately 10% sequentially, driven by contributions from Cohealyx® and improved RECELL® utilization as reimbursement dynamics normalizeAppointment of Cary Vance as President and Chief Executive Officer following a comprehensive search process led by a specia

    5/14/26 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical Names Cary Vance as Chief Executive Officer

    Board appoints Cary Vance as President and Chief Executive Officer Follows successful interim tenure and thorough search process by the Board Jan Stern Reed elected as Chair of the AVITA Medical Board VALENCIA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that its Board of Directors has appointed Cary Vance as President and Chief Executive Officer, effective immediately. The Board of Directors has also appointed Jan Stern Reed as its Chair, effective immediately. Mr. Vance, who has served as Interim CEO since October 2025, will continue to serve on the Board as an executive member.

    4/30/26 8:50:00 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical to Announce First Quarter 2026 Financial Results

    VALENCIA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Thursday, May 14, 2026. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 15, 2026, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights. First Quarter 2026 Webcast and Conference Call InformationTo listen to the conference call webcast, please register and join using the following link: https://edge.media-serve

    4/23/26 4:10:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avita Medical Inc.

    SC 13G - AVITA Medical, Inc. (0001762303) (Subject)

    2/13/24 4:58:57 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Avita Medical Inc.

    SC 13G - AVITA Medical, Inc. (0001762303) (Subject)

    1/26/24 4:23:41 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Avita Medical Inc. (Amendment)

    SC 13G/A - AVITA Medical, Inc. (0001762303) (Subject)

    2/9/23 11:07:47 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care